Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
In the latest session, Amicus Therapeutics Inc (NASDAQ: FOLD) closed at $14.28 down -0.14% from its previous closing price of $14.3. In other words, the price has decreased by -$0.14 from its previous closing price. On the day, 17.71 million shares were traded. FOLD stock price reached its highest trading level at $14.32 during the session, while it also had its lowest trading level at $14.27.
Ratios:
For a deeper understanding of Amicus Therapeutics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 16.74 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 455.82. For the most recent quarter (mrq), Quick Ratio is recorded 2.09 and its Current Ratio is at 2.99. In the meantime, Its Debt-to-Equity ratio is 1.92 whereas as Long-Term Debt/Eq ratio is at 1.88.
On December 22, 2025, TD Cowen Downgraded its rating to Hold which previously was Buy but kept the price unchanged to $14.50.
On December 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $17.Citigroup initiated its Buy rating on December 17, 2025, with a $17 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 19 ’25 when Clark David Michael sold 25,642 shares for $14.17 per share. The transaction valued at 363,380 led to the insider holds 245,690 shares of the business.
DAVID CLARK bought 25,642 shares of FOLD for $279,241 on Dec 19 ’25. On Dec 15 ’25, another insider, Campbell Bradley L, who serves as the President and CEO of the company, sold 77,926 shares for $10.86 each. As a result, the insider received 846,011 and left with 1,129,782 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FOLD now has a Market Capitalization of 4416832000 and an Enterprise Value of 4584837120. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.38 while its Price-to-Book (P/B) ratio in mrq is 19.12. Its current Enterprise Value per Revenue stands at 7.658 whereas that against EBITDA is 108.852.
Stock Price History:
The Beta on a monthly basis for FOLD is 0.38, which has changed by 0.5853659 over the last 52 weeks, in comparison to a change of 0.1877265 over the same period for the S&P500. Over the past 52 weeks, FOLD has reached a high of $14.36, while it has fallen to a 52-week low of $5.51. The 50-Day Moving Average of the stock is 31.60%, while the 200-Day Moving Average is calculated to be 78.72%.
Shares Statistics:
For the past three months, FOLD has traded an average of 9.65M shares per day and 12461510 over the past ten days. A total of 308.50M shares are outstanding, with a floating share count of 303.11M. Insiders hold about 2.00% of the company’s shares, while institutions hold 102.88% stake in the company. Shares short for FOLD as of 1765756800 were 19594481 with a Short Ratio of 2.03, compared to 1763078400 on 18036801. Therefore, it implies a Short% of Shares Outstanding of 19594481 and a Short% of Float of 6.39.
Earnings Estimates
Amicus Therapeutics Inc (FOLD) is presently subject to a detailed evaluation by 5.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $0.09, with high estimates of $0.14 and low estimates of $0.04.
Analysts are recommending an EPS of between $0.44 and $0.32 for the fiscal current year, implying an average EPS of $0.38. EPS for the following year is $0.65, with 5.0 analysts recommending between $0.79 and $0.56.
Revenue Estimates
A total of 9 analysts believe the company’s revenue will be $179.76M this quarter.It ranges from a high estimate of $184.74M to a low estimate of $174.31M. As of . The current estimate, Amicus Therapeutics Inc’s year-ago sales were $149.71MFor the next quarter, 9 analysts are estimating revenue of $161.59M. There is a high estimate of $172.6M for the next quarter, whereas the lowest estimate is $148.55M.
A total of 10 analysts have provided revenue estimates for FOLD’s current fiscal year. The highest revenue estimate was $635.5M, while the lowest revenue estimate was $623.3M, resulting in an average revenue estimate of $629.23M. In the same quarter a year ago, actual revenue was $528.29MBased on 10 analysts’ estimates, the company’s revenue will be $745.39M in the next fiscal year. The high estimate is $756.2M and the low estimate is $735.87M.
